Last updated on January 2020

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors


Brief description of study

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab tremelimumab in combination with chemoradiation in patients with advanced solid tumors

Detailed Study Description

This study will initially treat up to approximately 300 patients with advanced solid tumors at approximately 30 sites, worldwide. The study will be composed of a dose-limiting toxicity (DLT) assessment phase (Part A) and an expansion phase (Part B).

Clinical Study Identifier: NCT03509012

Find a site near you

Start Over

Research Site

Tucson, AZ United States
  Connect »

Research Site

Aurora, CO United States
  Connect »

Research Site

New Haven, CT United States
  Connect »

Research Site

Saint Louis, MO United States
  Connect »

Research Site

Middletown, NJ United States
  Connect »

Research Site

Sunto-gun, Japan
  Connect »

Research Site

Seoul, Korea, Republic of
  Connect »

Research Site

Kaohsiung, Taiwan
  Connect »

Research Site

Taichung, Taiwan
  Connect »

Research Site

Houston, TX United States
  Connect »

Research Site

Taoyuan City, Taiwan
  Connect »